Zyversa Therapeutics Inc Share Price

NASDAQ: ZVSA

$0.17

-0.02

(-10.62%)

as on September 18, 2025 at 12:46 am IST

$₹

The stock has been delisted from the stock exchange on 16 Jul 2025

Zyversa Therapeutics Inc Stock Performance

as on September 18, 2025 at 12:46 am IST

Day's Low
Day's High
$0.18
Day's Price Range
$0.18
$0.17
-5.88%
Downside
5.88%
Upside
52 Week's Low
52 Week's High
$0.27
52-Week Price Range
$3.37
$0.17
-58.82%
Downside
1882.35%
Upside

Zyversa Therapeutics Inc share price movements today

Previous Close: $0.18
Open: $0.18
Volume: 100.0
Day's Low - High: $0.18 - $0.18
52 Week Low - High: $0.27 - $3.37

Zyversa Therapeutics Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Zyversa Therapeutics Inc Stock Fundamentals & Key Indicators

Check Zyversa Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Zyversa Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Zyversa Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Zyversa Therapeutics Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Zyversa Therapeutics Inc Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Zyversa Therapeutics Inc. Average target price of $20

Zyversa Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Zyversa Therapeutics Inc.

What analysts predicted

99.15%UPSIDE

Target Price

$20

Current Price

$0.17

Analyzed by

8 Analysts

Target

$20.00

Zyversa Therapeutics Inc target price $20, a slight upside of 99.15% compared to current price of $0.17. According to 8 analysts rating.

Zyversa Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	-	-	-	-	0	0	-	-	0	-
Gross Profit	0	0	0	0	0	0	0	-	0	-
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-4	-3	-78	-2	-13	-2	-2	-2,401	-1	-2,256
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-85503.21%	-18120.11%	0.00%	0.00%	-5451.72%	0.00%

Zyversa Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	0	0	0	0	-
Operating Income	-	-	-	-	-
EBITDA	-	-	-	-	-
Interest Expense	-	-	-	-	-
Depreciation	-	-	-	-	-
Income Before Tax	-	-	-	-	-
Income Tax Expense	-	-	-	-	-
Net Income	-13	-8	-759	-98	-9,413
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

About Zyversa Therapeutics Inc

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.

Organisation	Zyversa Therapeutics Inc
E-voting on shares	Click here to vote

FAQs

What is Zyversa Therapeutics Inc share price today?

Zyversa Therapeutics Inc share price today is $0.17 as on September 18, 2025 at 12:46 am IST at the close of the market. Zyversa Therapeutics Inc share today touched a day high of $0.18 and a low of $0.18.

What is the 52 week high and 52 week low for Zyversa Therapeutics Inc share?

Zyversa Therapeutics Inc share touched a 52 week high of $3.37 on November 5, 2024 and a 52 week low of $0.27 on July 16, 2025. Zyversa Therapeutics Inc stock price today i.e. September 18, 2025 at 12:46 am IST is closed at $0.17,which is 94.96% down from its 52 week high and -37.04% up from its 52 week low.

How to invest in Zyversa Therapeutics Inc Stock (ZVSA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Zyversa Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zyversa Therapeutics Inc Shares that will get you 8.8235 shares as per Zyversa Therapeutics Inc share price of $0.17 per share as on September 18, 2025 at 12:46 am IST.

What is the minimum amount required to buy Zyversa Therapeutics Inc Stock (ZVSA) from India?

Indian investors can start investing in Zyversa Therapeutics Inc (ZVSA) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 11:37 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Zyversa Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 11:37 am IST). Based on Zyversa Therapeutics Inc share’s latest price of $0.17 as on September 18, 2025 at 12:46 am IST, you will get 58.8235 shares of Zyversa Therapeutics Inc. Learn more about fractional shares .